Evidence map›Paper›PMID 27773782›Full record

ReviewPharmacology & therapeutics2017

Obesity: Current and potential pharmacotherapeutics and targets.

Vidya Narayanaswami, Linda P Dwoskin

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 3 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 3 syntheses or guidelines pooled it, 181 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Combination Therapy: A New Tool for the Management of Obesity.Endocrine, metabolic & immune disorders drug targets · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Anti-Inflammatory Effect of Ethanolic Extract fromMolecules (Basel, Switzerland) · 2023
    Article
  18. Review
  19. Review
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Vidya NarayanaswamiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536, USA.
Linda P DwoskinDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536, USA. Electronic address: ldwoskin@email.uky.edu.
University of Kentucky · US

Funding

INDIVIDUAL DIFFERENCES IN DRUG RESPONSE--AN ANIMAL MODELP50DA005312 · UNIVERSITY OF KENTUCKY · 1987 to 2005
$4.4M
Kentucky Center for Clinical and Translational ScienceUL1TR001998 · UNIVERSITY OF KENTUCKY · 2025 to 2025
$3.3M
Angiotensin: A Link Between Obesity and HypertensionR01HL073085 · UNIVERSITY OF KENTUCKY · 2003 to 2005
$1.2M
NCATS NIH HHS UL1 TR000117NCATS NIH HHS UL1 TR001998NCRR NIH HHS P20 RR021954NHLBI NIH HHS R01 HL073085NIDA NIH HHS P50 DA005312NIGMS NIH HHS P20 GM103527
6 · The paper itself

Abstract

Obesity is a global epidemic that contributes to a number of health complications including cardiovascular disease, type 2 diabetes, cancer and neuropsychiatric disorders. Pharmacotherapeutic strategies to treat obesity are urgently needed. Research over the past two decades has increased substantially our knowledge of central and peripheral mechanisms underlying homeostatic energy balance. Homeostatic mechanisms involve multiple components including neuronal circuits, some originating in hypothalamus and brain stem, as well as peripherally-derived satiety, hunger and adiposity signals that modulate neural activity and regulate eating behavior. Dysregulation of one or more of these homeostatic components results in obesity. Coincident with obesity, reward mechanisms that regulate hedonic aspects of food intake override the homeostatic regulation of eating. In addition to functional interactions between homeostatic and reward systems in the regulation of food intake, homeostatic signals have the ability to alter vulnerability to drug abuse. Regarding the treatment of obesity, pharmacological monotherapies primarily focus on a single protein target. FDA-approved monotherapy options include phentermine (Adipex-P®), orlistat (Xenical®), lorcaserin (Belviq®) and liraglutide (Saxenda®). However, monotherapies have limited efficacy, in part due to the recruitment of alternate and counter-regulatory pathways. Consequently, a multi-target approach may provide greater benefit. Recently, two combination products have been approved by the FDA to treat obesity, including phentermine/topiramate (Qsymia®) and naltrexone/bupropion (Contrave®). The current review provides an overview of homeostatic and reward mechanisms that regulate energy balance, potential therapeutic targets for obesity and current treatment options, including some candidate therapeutics in clinical development. Finally, challenges in anti-obesity drug development are discussed.

Indexed as

Drug DesignAnimalsAnti-Obesity AgentsEatingHomeostasisHumansMolecular Targeted TherapyObesityRewardAnti-Obesity AgentsHomeostasisObesityPharmacotherapyReward

Identifiers

PMID27773782
PMCPMC5274590
OpenAlexW2534293284

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.